Femzole 2.5
- Femzole is a nonsteroidal aromatase inhibitor indicated for the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, as well as for hormone-dependent advanced breast cancer.
- It reduces estrogen biosynthesis, which is crucial for managing and treating hormone-sensitive cancers.
- Femzole is administered orally at 2.5 mg daily and is typically used for up to 5 years or until relapse.
- Common side effects include hot flashes, fatigue, and joint pain, while rare side effects may involve liver issues and nervous disorders.
- Store Femzole below 30°C, away from light and moisture, and keep out of reach of children.